Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pyridoxamine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pyridorin 150 mg bid |
| 2 | EXPERIMENTAL | Pyridorin 300 mg bid |
| 3 | PLACEBO_COMPARATOR | Placebo bid |
| Name | Type | Description |
|---|---|---|
| Pyridoxamine Dihydrochloride | DRUG | 150 mg capsules taken orally twice a day for 1-year. |
| Placebo | DRUG | Placebo capsules taken twice a day for 1-year |
INCLUSION CRITERIA: 1. Patients who have given voluntary written consent to participate in this study prior to conducting Screening Visit procedures; 2. Male and female patients 25 years of age or older with a diagnosis of type 2 diabetes; • If a woman is of childbearing potential (WOCBP) she must ...
Top 3 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Rilparencel |